A Phase 1 interventional study of OPC-34712 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-20.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.
Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 20th largest by enrollment, is the only one that started in 2010, is one of 8 in phase 1, and was the 4th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:
New York State Psychiatric Institute
Ages 18–55
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 17 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 155 across the 28 interventional studies. Of the 26 that completed or were terminated, 22 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 84th largest by enrollment of the 111 interventional ones that give a count, is one of 5 that started in 2010, is one of 34 in phase 1, and was the 37th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing brexpiprazole in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate how much of the investigational product gets into the blood stream and how long the body takes to get rid of it when given to subjects with a range of liver impairment compared to subjects with normal liver function.
This is a multi-center, open-label, parallel-arm study in 1 group of subjects with normal hepatic function and 3 groups of subjects with varying degrees of hepatic impairment (mild, moderate, and severe). Subjects will be confined to the clinic from Day -1 to Day 8. Subjects will be contacted via telephone 30 days (+ 2 days) after the last dose of study medication to assess any new or ongoing AEs and to record concomitant medications. All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria for Hepatically Impaired Subjects Only:
Inclusion Criteria for Subjects with Normal Hepatic Function Only
Exclusion Criteria:
Exclusion Criteria for Hepatically Impaired Subjects Only:
Exclusion Criteria for Subjects with Normal Hepatic Function Only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: OPC-34712
Drug: OPC-34712
Drug: OPC-34712
Drug: OPC-34712
All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.
Unbound Brexpiprazole Area Under the Concentration Time Curve (AUC) Calculated to the Last Observable Concentration at Time t (AUCt,u)
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/Early termination (ET).
Time frame: Day 1 to Day 8
Unbound Brexpiprazole AUC Calculated From Time Zero to Infinity (AUC∞,u)
Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUC (0 - ∞)= AUC from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: Day 1 to Day 8
Unbound Maximum Plasma Concentration of Brexpiprazole (Cmax,u)
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Cmax,u is the highest measured unbound plasma concentration during the dosing interval.
Time frame: Day 1 to Day 8
Area Under the Curve of Brexpiprazole Calculated to the Last Observable Concentration at Time t (AUCt)
Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUCt= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t) The AUCt was estimated using the linear trapezoidal rule.
Time frame: Day 1 to Day 8
Area Under the Concentration Time Curve of Brexpiprazole From Time Zero to Infinity (AUC∞)
Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUC (0 - ∞)= AUC from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). The AUC∞ was estimated using the linear trapezoidal rule
Time frame: Day 1 to Day 8
Maximum Plasma Concentration of Brexpiprazole (Cmax)
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Cmax is the highest measured concentration of the drug during the dosing interval. Actual blood sample times were used for PK calculations. Values for Cmax and tmax were determined directly from the observed data.
Time frame: Day 1 to Day 8
Time to Cmax of Brexiprazole (Tmax)
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Tmax is the time taken to reach highest measured concentration of the drug during the dosing interval. Actual blood sample times were used for PK calculations. Values for Cmax and tmax were determined directly from the observed data.
Time frame: Day 1 to Day 8
Apparent Clearance of Brexpiprazole From Plasma After Extravascular Administration (CL/F)
The value of CL/F (brexpiprazole only) was determined as Dose/AUC∞. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Day 1 to Day 8
Unbound Fraction of Brexpiprazole in Plasma (fu)
Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET.
Time frame: Day 1 to Day 8
Apparent Unbound Clearance of Brexpiprazole From Plasma After Extravascular Administration (CLu/F)
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The value of CLu/F (brexpiprazole only) was determined as dose normalized unbound area under the concentration-time curve from time zero to infinity (Dose/AUC∞,u).
Time frame: Day 1 to Day 8
Terminal-phase Elimination Half-life of Brexpiprazole (t1/2,z)
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The t1/2,z was determined as (ln2)/λz. Terminal-phase elimination half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Day 1 to Day 8
Renal Clearance (CLr) of Brexipiprazole
Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of CLr was calculated as Ae,u/AUCt.
Time frame: Day 1 to Day 8
Cumulative Amount of Brexpiprazole Excreted Into the Urine (Ae,u)
Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of Ae,u was calculated as the summation of urine concentration × urine volume from each collection interval
Time frame: Day 1 to Day 8
Fraction of Systemically Available Brexpiprazole Excreted Into the Urine (fe,u)
Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose.. The value of fe,u was calculated as 100 × Ae,u/Dose.
Time frame: Day 1 to Day 8
AUCt for DM-3411 Metabolite
Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUCt= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t) The AUCt was estimated using the linear trapezoidal rule.
Time frame: Day 1 to Day 8
AUC∞ for DM-3411 Metabolite
Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The AUC∞ were estimated using the linear trapezoidal rule.
Time frame: Day 1 to Day 8
Cmax for DM-3411 Metabolite
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Cmax is the highest measured concentration of the metabolite during the dosing interval.
Time frame: Day 1 to Day 8
Tmax for DM-3411 Metabolite
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Tmax is the time taken to reach highest measured concentration of the metabolite during the dosing interval.
Time frame: Day 1 to Day 8
t1/2,z for DM-3411 Metabolite
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The t1/2,z was determined as (ln2)/λz.
Time frame: Day 1 to Day 8
Ae,u for DM-3411 Metabolite
Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of Ae,u was calculated as the summation of urine concentration × urine volume from each collection interval.
Time frame: Day 1 to Day 8
fe,u for DM-3411 Metabolite
Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of fe,u was calculated as 100 × Ae,u/Dose.
Time frame: Day 1 to Day 8
CLr for DM-3411 Metabolite
Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of CLr was calculated as Ae,u/AUCt.
Time frame: Day 1 to Day 8
Number of Adverse Events (AEs) Reported
AEs were captured for all participants from the time the ICF was signed until the end of the study
Time frame: From the time the Informed Consent Form was signed, throughout the 8 day study up to 30 days after study drug administration.
Number of Participants With Changes From Baseline in Vital Signs Parameters.
Vital signs (including blood pressure, heart rate, temperature, and respiratory rate) were assessed at Screening, Day -1, Day 1 at predose (within 45 minutes prior to dosing), and 2, 4, 6, 8, 12, 24, 72, 120, and 168/ET hours postdose. Blood pressure and heart rate were taken with the subject in the supine (performed first), sitting, and standing
Time frame: Day -1 to Day 8
Number of Participants With Changes From Baseline in Electrocardiogram (ECG) Parameters.
Electrocardiograms were performed at Screening, Day -1, and Day 1 at predose (in triplicate; within 45 minutes prior to dosing), and 2, 4, 6, 8, 12, 24, 72, 120, and 168/ET hours postdose. Standard 12-lead ECGs were performed after the subject was supine and at rest for ≥ 10 minutes prior to the ECG.
Time frame: Day-1 to Day 8
Number of Participants With Changes From Baseline in Serum Chemistry, Hematology and Urinalysis Parameters.
Hematology, serum chemistry, and urinalysis, including prothrombin time, international normalized ratio, partial thromboplastin time, and activated partial thromboplastin time, were completed at Screening, Day -1, Day 3 (48 hours postdose), and Day 8 (168 hours postdose)/ET.
Time frame: Day -1 to Day 8
Incidence of Suicidality, Suicidal Behaviour or Suicidal Ideation as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
The Baseline version of the C-SSRS was administered at Screening. The Since Last Visit version of the C-SSRS was administered on Day 1 at predose and on Days 4 and 7.
Time frame: Day 1, Day 4, Day 7
81 participants were screened; of these 45 participants were enrolled recruited at 3 study sites in the United States (US).
| Milestone | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Normal Hepatic Function |
|---|---|---|---|---|
| Started | 8 | 8 | 6 | 23 |
| Completed | 8 | 8 | 6 | 23 |
| Not completed | 0 | 0 | 0 | 0 |
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/Early termination (ET).
| nanograms.hours/mL (ng*h/mL) | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function | Moderate Hepatic Impairment | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Impairment | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Unbound Brexpiprazole Area Under the Concentration Time Curve (AUC) Calculated to the Last Observable Concentration at Time t (AUCt,u) | 5.95 ± 2.58 | 4.87 ± 1.78 | 5.41 ± 1.37 | 4.28 ± 1.95 | 3.27 ± 0.93 | 3.63 ± 1.54 |
Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUC (0 - ∞)= AUC from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
| ng*h/mL | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Impairment. | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Function | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Unbound Brexpiprazole AUC Calculated From Time Zero to Infinity (AUC∞,u) | 8.59 ± 5.29 | 5.85 ± 3.11 | 8.50 ± 2.17 | 5.62 ± 3.13 | 3.49 ± 0.848 | 3.36 ± 0.871 |
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Cmax,u is the highest measured unbound plasma concentration during the dosing interval.
| ng/mL | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Impairment | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Impairment | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Unbound Maximum Plasma Concentration of Brexpiprazole (Cmax,u) | 0.104 ± 0.0259 | 0.114 ± 0.0270 | 0.0648 ± 0.0143 | 0.0779 ± 0.0224 | 0.0392 ± 0.0105 | 0.0760 ± 0.0258 |
Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUCt= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t) The AUCt was estimated using the linear trapezoidal rule.
| ng*h/mL | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Impairment | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Impairment | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Area Under the Curve of Brexpiprazole Calculated to the Last Observable Concentration at Time t (AUCt) | 1271 ± 569 | 1145 ± 539 | 1213 ± 405 | 1048 ± 422 | 622 ± 163 | 817 ± 306 |
Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUC (0 - ∞)= AUC from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). The AUC∞ was estimated using the linear trapezoidal rule
| ng*h/mL | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Impairment | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Impairment | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Area Under the Concentration Time Curve of Brexpiprazole From Time Zero to Infinity (AUC∞) | 1827 ± 1103 | 1393 ± 881 | 1960 ± 579 | 1345 ± 697 | 831 ± 234 | 788 ± 230 |
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Cmax is the highest measured concentration of the drug during the dosing interval. Actual blood sample times were used for PK calculations. Values for Cmax and tmax were determined directly from the observed data.
| ng/mL | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Impairment | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Impairment | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Maximum Plasma Concentration of Brexpiprazole (Cmax) | 22.9 ± 7.60 | 26.7 ± 9.09 | 14.6 ± 4.63 | 19.3 ± 4.98 | 7.65 ± 2.69 | 17.7 ± 7.38 |
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Tmax is the time taken to reach highest measured concentration of the drug during the dosing interval. Actual blood sample times were used for PK calculations. Values for Cmax and tmax were determined directly from the observed data.
| h | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Impairment | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Function | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Time to Cmax of Brexiprazole (Tmax) | 3.50 (1.00 to 5.00) | 3.50 (2.00 to 5.00) | 4.50 (3.00 to 24.0) | 4.50 (1.00 to 6.00) | 5.00 (4.00 to 24.0) | 5.00 (2.00 to 6.00) |
The value of CL/F (brexpiprazole only) was determined as Dose/AUC∞. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| mL/h/kg | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Impairment | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Impairment | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Apparent Clearance of Brexpiprazole From Plasma After Extravascular Administration (CL/F) | 24.5 ± 28.2 | 25.4 ± 12.3 | 13.8 ± 2.72 | 26.0 ± 19.2 | 28.2 ± 6.70 | 34.2 ± 16.3 |
Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET.
| % unbound drug in the urine | Mild Hepatic Function | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Function | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Function | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Unbound Fraction of Brexpiprazole in Plasma (fu) | 0.472 ± 0.0840 | 0.451 ± 0.112 | 0.462 ± 0.0786 | 0.400 ± 0.0442 | 0.544 ± 0.186 | 0.450 ± 0.0795 |
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The value of CLu/F (brexpiprazole only) was determined as dose normalized unbound area under the concentration-time curve from time zero to infinity (Dose/AUC∞,u).
| mL/h/kg | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Function | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Function | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Apparent Unbound Clearance of Brexpiprazole From Plasma After Extravascular Administration (CLu/F) | 5674 ± 7165 | 5730 ± 2944 | 3115 ± 494 | 6768 ± 5833 | 6598 ± 1182 | 7697 ± 2653 |
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The t1/2,z was determined as (ln2)/λz. Terminal-phase elimination half-life is the time measured for the plasma concentration to decrease by one half.
| h | Mild Hepatic Function | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Function | Normal Hepatic Function Matched to Moderate Hepatic Function. | Sever Hepatic Function | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Terminal-phase Elimination Half-life of Brexpiprazole (t1/2,z) | 103 ± 51.1 | 64.7 ± 24.6 | 116 ± 25.8 | 64.2 ± 26.2 | 81.1 ± 17.1 | 51.4 ± 8.21 |
Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of CLr was calculated as Ae,u/AUCt.
| mL/h/kg | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Impairment | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Impairment | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Renal Clearance (CLr) of Brexipiprazole | 0.0468 ± 0.0353 | 0.0263 ± 0.0244 | 0.0360 ± 0.0286 | 0.0422 ± 0.0383 | 0.0402 ± 0.0872 | 0.0193 ± 0.0203 |
Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of Ae,u was calculated as the summation of urine concentration × urine volume from each collection interval
| ng | Mild Hepatic Function | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Function | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Function | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Cumulative Amount of Brexpiprazole Excreted Into the Urine (Ae,u) | 4511 ± 3808 | 1854 ± 1500 | 3522 ± 2740 | 3837 ± 3358 | 2090 ± 4699 | 1326 ± 1427 |
Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose.. The value of fe,u was calculated as 100 × Ae,u/Dose.
| % of drug in urine | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Impairment | Normal Hepatic Function Matched to Moderate Hepatic Function | Severe Hepatic Impairment | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Fraction of Systemically Available Brexpiprazole Excreted Into the Urine (fe,u) | 0.226 ± 0.190 | 0.0927 ± 0.0750 | 0.176 ± 0.137 | 0.192 ± 0.168 | 0.104 ± 0.235 | 0.0663 ± 0.0713 |
Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. AUCt= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t) The AUCt was estimated using the linear trapezoidal rule.
| ng*h/mL | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Impairment | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Impairment | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| AUCt for DM-3411 Metabolite | 380 ± 195 | 683 ± 246 | 284 ± 164 | 486 ± 263 | 151 ± 51.4 | 479 ± 226 |
Blood samples were taken at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The AUC∞ were estimated using the linear trapezoidal rule.
| ng*h/mL | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Impairment | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Impairment | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| AUC∞ for DM-3411 Metabolite | 489 ± 210 | 692 ± 259 | 382 ± 262 | 530 ± 211 | 187 ± 67.2 | 329 ± 167 |
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Cmax is the highest measured concentration of the metabolite during the dosing interval.
| ng/mL | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Impairment | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Impairment | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Cmax for DM-3411 Metabolite | 6.49 ± 5.13 | 10.5 ± 4.26 | 3.19 ± 1.56 | 7.25 ± 4.83 | 2.15 ± 0.880 | 7.13 ± 3.73 |
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. Tmax is the time taken to reach highest measured concentration of the metabolite during the dosing interval.
| h | Mild Hepatic Function | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Function | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Function | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Tmax for DM-3411 Metabolite | 5.00 (2.00 to 24.0) | 6.00 (5.00 to 24.0) | 5.00 (2.00 to 24.0) | 7.00 (2.00 to 24.0) | 4.5 (3.00 to 24.0) | 6.00 (5.00 to 16.0) |
Blood samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, and 168 hours postdose/ET. The t1/2,z was determined as (ln2)/λz.
| h | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Impairment | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Impairment | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| t1/2,z for DM-3411 Metabolite | 78.8 ± 37.6 | 59.7 ± 15.7 | 87.2 ± 45.7 | 62.0 ± 26.4 | 84.6 ± 12.0 | 56.1 ± 8.25 |
Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of Ae,u was calculated as the summation of urine concentration × urine volume from each collection interval.
| ng | Mild Hepatic Function | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Function | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Function | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| Ae,u for DM-3411 Metabolite | 67086 ± 25276 | 81148 ± 23188 | 68413 ± 16993 | 71353 ± 41630 | 48190 ± 14756 | 83604 ± 34907 |
Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of fe,u was calculated as 100 × Ae,u/Dose.
| % metabolite excreted in urine | Mild Hepatic Function | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Function | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Function | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| fe,u for DM-3411 Metabolite | 3.23 ± 1.22 | 3.91 ± 1.12 | 3.30 ± 0.819 | 3.44 ± 2.01 | 2.32 ± 0.712 | 4.03 ± 1.68 |
Urine samples were taken at pre-dose and during the following increments: 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 hours postdose. The value of CLr was calculated as Ae,u/AUCt.
| mL/h/kg | Mild Hepatic Impairment | Normal Hepatic Function Matched to Mild Hepatic Function. | Moderate Hepatic Impairment | Normal Hepatic Function Matched to Moderate Hepatic Function. | Severe Hepatic Impairment | Normal Hepatic Function Matched to Severe Hepatic Function. |
|---|---|---|---|---|---|---|
| CLr for DM-3411 Metabolite | 2.67 ± 1.31 | 1.83 ± 0.828 | 3.96 ± 2.32 | 1.90 ± 0.568 | 4.08 ± 1.68 | 2.33 ± 1.01 |
AEs were captured for all participants from the time the ICF was signed until the end of the study
| Events | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Normal Hepatic Function |
|---|---|---|---|---|
| Adverse events | 3 | 5 | 1 | 8 |
| Treatment emergent adverse events | 3 | 5 | 1 | 6 |
| Serious adverse events | 0 | 0 | 0 | 0 |
Vital signs (including blood pressure, heart rate, temperature, and respiratory rate) were assessed at Screening, Day -1, Day 1 at predose (within 45 minutes prior to dosing), and 2, 4, 6, 8, 12, 24, 72, 120, and 168/ET hours postdose. Blood pressure and heart rate were taken with the subject in the supine (performed first), sitting, and standing
| Participants | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Normal Hepatic Function |
|---|---|---|---|---|
| Number of Participants With Changes From Baseline in Vital Signs Parameters. | 0 | 0 | 0 | 0 |
Electrocardiograms were performed at Screening, Day -1, and Day 1 at predose (in triplicate; within 45 minutes prior to dosing), and 2, 4, 6, 8, 12, 24, 72, 120, and 168/ET hours postdose. Standard 12-lead ECGs were performed after the subject was supine and at rest for ≥ 10 minutes prior to the ECG.
| Participants | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Normal Hepatic Function |
|---|---|---|---|---|
| Number of Participants With Changes From Baseline in Electrocardiogram (ECG) Parameters. | 0 | 0 | 0 | 0 |
Hematology, serum chemistry, and urinalysis, including prothrombin time, international normalized ratio, partial thromboplastin time, and activated partial thromboplastin time, were completed at Screening, Day -1, Day 3 (48 hours postdose), and Day 8 (168 hours postdose)/ET.
| Participant | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Normal Hepatic Function |
|---|---|---|---|---|
| Number of Participants With Changes From Baseline in Serum Chemistry, Hematology and Urinalysis Parameters. | 0 | 0 | 0 | 0 |
The Baseline version of the C-SSRS was administered at Screening. The Since Last Visit version of the C-SSRS was administered on Day 1 at predose and on Days 4 and 7.
| Participants | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Normal Hepatic Function |
|---|---|---|---|---|
| Incidence of Suicidality, Suicidal Behaviour or Suicidal Ideation as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS) | 0 | 0 | 0 | 0 |
Collected over Adverse events were recorded from the time the Informed Consent Form was signed, throughout the 8 day study up to 30 days after study drug administration.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mild Hepatic Impairment | — | 0/8 (0%) | 3/8 (37.5%) |
| Moderate Hepatic Impairment | — | 0/8 (0%) | 3/8 (37.5%) |
| Severe Hepatic Impairment | — | 0/6 (0%) | 1/6 (16.7%) |
| Normal Hepatic Function | — | 0/23 (0%) | 6/23 (26.1%) |
| Event | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Normal Hepatic Function |
|---|---|---|---|---|
| HeadacheNervous system disorders | 1/8 | 1/8 | 1/6 | 4/23 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 1/8 | 0/6 | 0/23 |
| FatigueGeneral disorders | 1/8 | 1/8 | 0/6 | 0/23 |
| DizzinessNervous system disorders | 1/8 | 0/8 | 0/6 | 0/23 |
| SomnolenceNervous system disorders | 0/8 | 1/8 | 0/6 | 1/23 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/8 | 1/8 | 0/6 | 0/23 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/8 | 0/8 | 0/6 | 1/23 |
| Age, Continuous(Years) | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Normal Hepatic Function | Total |
|---|---|---|---|---|---|
| Mean | 59.5 ± 7.3 | 57.8 ± 3.8 | 51.2 ± 4.4 | 56.2 ± 5.2 | 56.4 ± 5.7 |
| Sex: Female, Male(Participants) | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment | Normal Hepatic Function | Total |
|---|---|---|---|---|---|
| Female | 3 | 2 | 0 | 5 | 10 |
| Male | 5 | 6 | 6 | 18 | 35 |
The record gives a start of Dec 2010, a primary completion of Jun 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 4 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →